Latest news with #MedicinePriceDisplay
The Sun
13-05-2025
- Health
- The Sun
MOH mulls medicine price display under Act 586
PUTRAJAYA: The Ministry of Health (MOH) is considering a proposal from the Malaysian Medical Association (MMA) to implement the Medicine Price Display initiative under the Private Healthcare Facilities and Services Act 1998 (Act 586). Its minister, Datuk Dr Dzulkefly Ahmad said the proposal, which is among the matters raised in a memorandum submitted by the MMA, has received the attention of Prime Minister Datuk Seri Anwar Ibrahim, who has advised the MOH to study and evaluate it. 'The Prime Minister has asked me to carefully review their memorandum, and I have taken this matter seriously. 'I have directed the top leadership of the MOH to look into how we can address the request fairly and consider the feasibility of placing the medicine price display requirement under Act 586, which falls under the ministry's purview,' he told a press conference after attending the 2025 National Midwives and Nurses Day celebration here today. Dr Dzulkefly added that the MOH is committed to being responsive and welcomes constructive suggestions aimed at strengthening the country's healthcare system. On Tuesday, the MMA urged the government to review the use of the Price Control and Anti-Profiteering Act 2011 (Act 723) in the medical sector, particularly with regard to the recent regulation requiring private clinics and pharmacies to display the prices of medicines, which came into effect earlier this month. In its memorandum, the MMA expressed full support for transparency in drug pricing but argued that it should be implemented through Act 586. The regulation on price display, enforced from May 1, is outlined under the Price Control and Anti-Profiteering (Price Marking for Drugs) Order 2025, issued under Act 723. The scope covers all medicines for human use, including controlled medicines, over-the-counter drugs, traditional products, health supplements, and extemporaneous preparations — both prescription and non-prescription. In a related development, Dr Dzulkefly said the MOH is finalising a review of consultation fees for private general practitioners (GPs), which is expected to be presented to the Cabinet by the end of this month. On May 3, Dr Dzulkefly had given an assurance that the review would be concluded within a month.
The Sun
13-05-2025
- Health
- The Sun
MOH to review MMA's proposal on medicine price display under Act 586
PUTRAJAYA: The Ministry of Health (MOH) is considering a proposal from the Malaysian Medical Association (MMA) to implement the Medicine Price Display initiative under the Private Healthcare Facilities and Services Act 1998 (Act 586). Its minister, Datuk Dr Dzulkefly Ahmad said the proposal, which is among the matters raised in a memorandum submitted by the MMA, has received the attention of Prime Minister Datuk Seri Anwar Ibrahim, who has advised the MOH to study and evaluate it. 'The Prime Minister has asked me to carefully review their memorandum, and I have taken this matter seriously. 'I have directed the top leadership of the MOH to look into how we can address the request fairly and consider the feasibility of placing the medicine price display requirement under Act 586, which falls under the ministry's purview,' he told a press conference after attending the 2025 National Midwives and Nurses Day celebration here today. Dr Dzulkefly added that the MOH is committed to being responsive and welcomes constructive suggestions aimed at strengthening the country's healthcare system. On Tuesday, the MMA urged the government to review the use of the Price Control and Anti-Profiteering Act 2011 (Act 723) in the medical sector, particularly with regard to the recent regulation requiring private clinics and pharmacies to display the prices of medicines, which came into effect earlier this month. In its memorandum, the MMA expressed full support for transparency in drug pricing but argued that it should be implemented through Act 586. The regulation on price display, enforced from May 1, is outlined under the Price Control and Anti-Profiteering (Price Marking for Drugs) Order 2025, issued under Act 723. The scope covers all medicines for human use, including controlled medicines, over-the-counter drugs, traditional products, health supplements, and extemporaneous preparations — both prescription and non-prescription. In a related development, Dr Dzulkefly said the MOH is finalising a review of consultation fees for private general practitioners (GPs), which is expected to be presented to the Cabinet by the end of this month. On May 3, Dr Dzulkefly had given an assurance that the review would be concluded within a month.
The Star
13-05-2025
- Health
- The Star
Health Ministry to review MMA proposal on medicine price display
PUTRAJAYA: The Health Ministry is considering a proposal from the Malaysian Medical Association (MMA) to implement the Medicine Price Display initiative under the Private Healthcare Facilities and Services Act 1998 (Act 586). Its minister Datuk Dr Dzulkefly Ahmad said the proposal, which is among the matters raised in a memorandum submitted by the MMA, has received the attention of Prime Minister Datuk Seri Anwar Ibrahim, who has advised the ministry to study and evaluate it. "The Prime Minister has asked me to carefully review their memorandum, and I have taken this matter seriously. "I have directed the ministry's top leadership to look into how we can address the request fairly and consider the feasibility of placing the medicine price display requirement under Act 586, which falls under the ministry's purview,' he told a press conference after attending the 2025 National Midwives and Nurses Day celebration here on Tuesday (May 13). Dr Dzulkefly added that the ministry is committed to being responsive and welcomes constructive suggestions aimed at strengthening the country's healthcare system. On Tuesday, the ministry urged the government to review the use of the Price Control and Anti-Profiteering Act 2011 (Act 723) in the medical sector, particularly with regard to the recent regulation requiring private clinics and pharmacies to display the prices of medicines, which came into effect earlier this month. In its memorandum, the MMA expressed full support for transparency in drug pricing but argued that it should be implemented through Act 586. The regulation on price display, enforced from May 1, is outlined under the Price Control and Anti-Profiteering (Price Marking for Drugs) Order 2025, issued under Act 723. The scope covers all medicines for human use, including controlled medicines, over-the-counter drugs, traditional products, health supplements, and extemporaneous preparations - both prescription and non-prescription. In a related development, Dr Dzulkefly said the ministry is finalising a review of consultation fees for private general practitioners (GPs), which is expected to be presented to the Cabinet by the end of this month. On May 3, Dr Dzulkefly had said that the review would be concluded within a month. - Bernama
Barnama
13-05-2025
- Health
- Barnama
MOH To Review MMA's Proposal On Medicine Price Display Under Act 586
GENERAL PUTRAJAYA, May 13 (Bernama) -- The Ministry of Health (MOH) is considering a proposal from the Malaysian Medical Association (MMA) to implement the Medicine Price Display initiative under the Private Healthcare Facilities and Services Act 1998 (Act 586). Its minister, Datuk Dr Dzulkefly Ahmad said the proposal, which is among the matters raised in a memorandum submitted by the MMA, has received the attention of Prime Minister Datuk Seri Anwar Ibrahim, who has advised the MOH to study and evaluate it. 'The Prime Minister has asked me to carefully review their memorandum, and I have taken this matter seriously. 'I have directed the top leadership of the MOH to look into how we can address the request fairly and consider the feasibility of placing the medicine price display requirement under Act 586, which falls under the ministry's purview,' he told a press conference after attending the 2025 National Midwives and Nurses Day celebration here today. Dr Dzulkefly added that the MOH is committed to being responsive and welcomes constructive suggestions aimed at strengthening the country's healthcare system. On Tuesday, the MMA urged the government to review the use of the Price Control and Anti-Profiteering Act 2011 (Act 723) in the medical sector, particularly with regard to the recent regulation requiring private clinics and pharmacies to display the prices of medicines, which came into effect earlier this month. In its memorandum, the MMA expressed full support for transparency in drug pricing but argued that it should be implemented through Act 586. The regulation on price display, enforced from May 1, is outlined under the Price Control and Anti-Profiteering (Price Marking for Drugs) Order 2025, issued under Act 723. The scope covers all medicines for human use, including controlled medicines, over-the-counter drugs, traditional products, health supplements, and extemporaneous preparations — both prescription and non-prescription.
The Sun
06-05-2025
- Health
- The Sun
Medicine price display facilitates fair comparisons
KUALA LUMPUR: The implementation of the Medicine Price Display Order at private healthcare facilities and pharmacies not only protects consumer rights but also allows insurance companies to compare the displayed medicine prices with those charged by private hospitals and clinics. Professor of Health Economics, Policy and Management at IMU University Prof Datuk Dr Syed Mohamed Aljunid Syed Junid said this would allow insurance providers to make fairer comparisons and engage in more transparent negotiations with panel health facilities, while also fostering more affordable and competitive pricing in the market. 'This move is one of the key building blocks in transforming the country's health system, particularly in addressing rising health inflation and ensuring access to quality medicines at reasonable prices. 'The transparency of the price display makes regulation easier, as there are clinics that may mark up prices unreasonably. 'This allows insurance companies to investigate, analyse, and take appropriate action when processing patient claims for treatment at private hospitals or clinics,' he said when appearing as a guest on the Temu Bual Radio programme aired on Bernama Radio today. According to Dr Syed Mohamed Aljunid, the Medicine Price Display initiative was introduced to improve transparency in medicine pricing, enabling consumers to make informed and smarter decisions when purchasing medicines according to their affordability. 'Consumers can now view medicine prices before making a purchase, helping to prevent hidden costs or excessive pricing. This initiative also allows them to compare prices across healthcare providers and make informed choices. 'The move introduced by the government aims to prevent consumers from being burdened with unreasonable charges for medicines,' he said. In response to concerns that the initiative may affect private medical practitioners or GPs, Dr Syed Mohamed Aljunid said that the effort was not intended to disrupt GP services or their operating models but rather to enhance the transparency of the existing system. 'What the government is doing is displaying medicine prices, not controlling them. Private facility doctors can set prices they deem appropriate. The government does not set prices, allowing these parties to establish their own prices based on the cost of purchasing medicines,' he said.
